Bayer Forecast, price target & analysts
Why the stock moved Beta
Bayer Target price 2025 - Analyst rating & recommendation
Bayer Classifications & Recommendation:
Bayer Price Target
| Target Price | €28.56 |
| Price | €29.06 |
| Deviation | 1.72% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €28.56. This is 1.72% lower than the current stock price. The highest price target is €36.75 26.46% , the lowest is €23.23 20.06% . | |
| A rating was issued by 28 analysts: 12 Analysts recommend Bayer to buy, 15 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 1.72% . Most analysts recommend the Bayer stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2032
24 Analysts have issued a sales forecast Bayer 2025 . The average Bayer sales estimate is €46.6b . This is 0.96% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €48.8b 5.78% , the lowest is €44.2b 4.36% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €46.6b | 2.16% |
|---|---|---|
| 2025 | €46.6b | 0.03% |
| 2026 | €47.0b | 0.87% |
| 2027 | €48.1b | 2.25% |
| 2028 | €50.3b | 4.57% |
| 2029 | €50.9b | 1.23% |
| 2030 | €52.6b | 3.43% |
| 2031 | €51.0b | 3.09% |
| 2032 | €51.7b | 1.33% |
22 Analysts have issued an Bayer EBITDA forecast 2025. The average Bayer EBITDA estimate is €9.5b . This is 43.26% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €10.2b 54.49% , the lowest is €7.7b 16.94% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €12.8b | 30.71% |
|---|---|---|
| 2025 | €9.5b | 25.75% |
| 2026 | €10.0b | 4.88% |
| 2027 | €10.4b | 4.75% |
| 2028 | €9.7b | 6.70% |
| 2029 | €9.7b | 0.73% |
EBITDA Margin
| 2024 | 27.42% | 29.18% |
|---|---|---|
| 2025 | 20.35% | 25.78% |
| 2026 | 21.16% | 3.98% |
| 2027 | 21.68% | 2.46% |
| 2028 | 19.34% | 10.79% |
| 2029 | 18.97% | 1.91% |
23 Bayer Analysts have issued a net profit forecast 2025. The average Bayer net profit estimate is €4.6b . This is 235.72% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €5.4b 256.93% , the lowest is €4.2b 223.94% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €-2.6b | 13.23% |
|---|---|---|
| 2025 | €4.6b | 281.77% |
| 2026 | €4.8b | 3.20% |
| 2027 | €5.2b | 9.41% |
| 2028 | €5.7b | 8.26% |
| 2029 | €5.7b | 1.25% |
| 2030 | €6.4b | 10.92% |
Net Margin
| 2024 | -5.48% | 11.31% |
|---|---|---|
| 2025 | 9.95% | 281.71% |
| 2026 | 10.18% | 2.31% |
| 2027 | 10.89% | 6.97% |
| 2028 | 11.28% | 3.58% |
| 2029 | 11.28% | 0.00% |
| 2030 | 12.10% | 7.27% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
23 Analysts have issued a Bayer forecast for earnings per share. The average Bayer EPS is €4.72 . This is 235.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is €5.46 256.90% , the lowest is €4.31 223.85% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €-2.60 | 13.04% |
|---|---|---|
| 2025 | €4.72 | 281.54% |
| 2026 | €4.87 | 3.18% |
| 2027 | €5.33 | 9.45% |
| 2028 | €5.77 | 8.26% |
| 2029 | €5.84 | 1.21% |
| 2030 | €6.48 | 10.96% |
| 2031 | €4.70 | 27.47% |
| 2032 | €4.86 | 3.40% |
P/E ratio
| Current | -7.88 | 70.54% |
|---|---|---|
| 2025 | 5.81 | 173.71% |
| 2026 | 5.63 | 3.10% |
| 2027 | 5.14 | 8.70% |
| 2028 | 4.75 | 7.59% |
| 2029 | 4.69 | 1.26% |
| 2030 | 4.23 | 9.81% |
Based on analysts' sales estimates for 2025, the Bayer stock is valued at an EV/Sales of 1.26 and an P/S ratio of 0.56 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.28 | 2.40% |
|---|---|---|
| 2025 | 1.26 | 1.18% |
| 2026 | 1.25 | 0.86% |
| 2027 | 1.23 | 2.21% |
| 2028 | 1.17 | 4.37% |
| 2029 | 1.16 | 1.21% |
| 2030 | 1.12 | 3.31% |
| 2031 | 1.16 | 3.19% |
| 2032 | 1.14 | 1.31% |
P/S ratio
| Current | 0.56 | 11.40% |
|---|---|---|
| 2025 | 0.56 | 0.94% |
| 2026 | 0.55 | 0.88% |
| 2027 | 0.54 | 2.20% |
| 2028 | 0.52 | 4.36% |
| 2029 | 0.51 | 1.22% |
| 2030 | 0.49 | 3.32% |
| 2031 | 0.51 | 3.20% |
| 2032 | 0.50 | 1.31% |
Current Bayer Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Sep 11 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Aug 29 2025 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 25 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Aug 18 2025 |
| SOLVENTIS RESEARCH |
Buy
➜
Buy
|
Unchanged | Aug 13 2025 |
| ROTHSCHILD & CO REDBURN |
Neutral
➜
Neutral
|
Unchanged | Aug 13 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Aug 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Sep 11 2025 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Aug 29 2025 |
|
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Buy
|
Aug 25 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Aug 18 2025 |
|
Unchanged
SOLVENTIS RESEARCH:
Buy
➜
Buy
|
Aug 13 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Neutral
➜
Neutral
|
Aug 13 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Aug 12 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
